FDA grants platform technology designation to Precigen's AdenoVerse immunotherapy platform

The U.S. Food and Drug Administration has granted a platform technology designation to Precigen Inc.'s AdenoVerse immunotherapy platform, a move that could expedite the development of future AdenoVerse-based therapies by allowing the use of manufacturing and preclinical data from the PAPZIMEOS treatment. PAPZIMEOS is an FDA-approved therapy for recurrent respiratory papillomatosis, which received clearance in August 2025.